Excited for the 3rd Collaboration for Outcomes using Social Media in Oncology meeting. All are welcome, MD not required. LOL.
The goal is to learn from each other. No more silos.

For people with metastatic PDL1+ TRIPLE NEG BREAST CANCER, Sacituzumab+pembrolizumab (P) significantly increases PFI by ~3m vs chemo+P (a 35% improvement). Whether its meaningful depends on the person offered it and whether it will ultimately improve OS. #ASCENT meetings.asco.org/abstracts-pr... 8/8

For people with advanced hormone receptor positive PIK3CA mutated BREAST CANCER, 1st line tx w/ inavolisib|palbociclib|fulvestrant (PF) increased OS over placebo + PF by 7 months- an almost 30% improvement. 30-month overall survival was also improved by 10%. meetings.asco.org/abstracts-pr... 7/8

Its not a randomized trial, but the results are reassuring. #KCSGBR18-2 www.asco.org/abstracts-pr... 6b/8

For people with metastatic triple-positive BREAST CANCER (Hormone and HER2 positive), one trial of 77p reported that ribociclib, trastuzumab, and letrozole resulted in a 61% overall response rate and median progression-free interval of 30 months. 6a/8

Whether monitoring blood for ctDNA over time improves overall survival through earlier intervention has to be proven. But the best med will always be the one someone is willing to stay on. #SERENA6 meetings.asco.org/abstracts-pr... 5b/8

In the absence of frank disease progression, for people with hormone-positive BREAST CANCER, the only reason to switch treatment from an aromatase inhibitor (AI) to a selective estrogen receptor degrader (SERD) is if toxicity is making it hard to take the AI. 5a/8

Interestingly, the OS benefit was bigger than the Progression Free Interval which was improved by only one month. It also added no additional toxicity to treatment. 4b/8 #ROSELLA ascopubs.org/doi/10.1200/...

For people with platinum-resistant recurrent OVARIAN CANCER, a novel drug that targets the glucocorticoid receptor, called Relacorilant, in combination with nAb-paclitaxel improved overall survival (OS) by 5 months over nAb-paclitaxel alone. 4a/8 #ROSELLA

For people with OVARIAN CANCER, surgery should be done if their gyn onc feels they can have all tumor resected rather than undergoing medical therapy (neo adjuvant chemo) first. That’s been the standard everywhere I’ve worked and the #TRUST trial affirms this. meetings.asco.org/abstracts-pr... 3/8

PFS (Progression Free Survival) needs to be renamed. People don’t experience “progression”. A cancer may progress at some interval, and that’s what it should be called: PFI. The only survival is whether one is alive or dead- OS (Overall Survival). We need to stop conflating them. 2/8

As I make my way home from #Chicago (finally!) here's what I come away with from #ASCO25
I had hoped to live blog from the meeting but time got the better of me! Here goes.... 1/8

Yes, so great to see you

Have fun at your #asco25 session. I will be watching remotely and rooting for you all the same.

I shared the ASCO stage with Dr Dawn Hershman when we were both awarded a career development award as we were starting our careers. Amazing to share the stage with her again as we are awarded once more at #ASCO25. Truly honored and excited to do so.

Blush

I'm officially Professor of Medicine at @tuftsmedschool.bsky.social
Yowza.

I'm proud to be a part of this international community seeking to improve both access and outcomes for people with breast cancer worldwide.

a great 4d in #Munich with @myesmo.bsky.social. Spoke on the importance of sex after cancer & chaired a session on Breast Cancer in Young Women. With @tanjaspanic.bsky.social from #Slovenia my pal Matteo Lambertini from #Italy, Prof Inez Vaz-Luis from #France, and Antigoni Kretsi from #Greece

… and Molly is not alone. More than $2.6B of ongoing research has been canceled (with much more this week, at Harvard).

With each cancellation: We are losing so much knowledge. Losing the next generation of scientists. Losing our ability to protect our health, both now & for the future. 🧪🩺😷

Breast Oncologist in Boston, Massachusetts, 02111-1552 | Physicians and Advanced Practice Clinicians at Tufts Medicine Apply for Breast Oncologist job with Tufts Medicine in Boston, Massachusetts, 02111-1552. Physicians and Advanced Practice Clinicians at Tufts Medicine

Leaving for #Munich next week for #ESMOBreast25 Excited to catch up w/ colleagues, especially as I renew my practice in breast oncology @tuftsmedicine.bsky.social If you are interested in joining me, we have a pretty great opportunity! Check it out and LMK.
careers.tuftsmedicine.org/us/en/job/R1...

The community engagement session led by @drdonsdizon.bsky.social at #SCHD25 demonstrated impactful outcomes. The work of Dr. Memnun Seven with cancer survivors, Dr. Andrew Sussman's CAB strategies, and Dr. Vida Henderson's media approaches show that authentic partnerships improve results.

I'm not practicing much but I am who I am because of my very Catholic parents who taught me right from wrong and to care for everybody. I admired Pope Francis. He will be missed in this very turbulent world.

Huge congratulations!!!!

ASCO Education: The Evolution of the ASCO Educational Book and the Issues Shaping the Future of Oncology On the inaugural episode of ASCO Education: By the Book, Dr. Nathan Pennell and Dr. Don Dizon share reflections on the evolution of the ASCO Educational Book, its global reach, and the role of its new...

So excited to kick off the first episode of our new podcast: ASCO Education: By the Book with good friend and former #EdBook editor @drdonsdizon.bsky.social!

@ascocancer.bsky.social ascoeducation.libsyn.com/the-evolutio...

Sexuality is so innately human we need to be able to talk about it for people with cancer. Join me, Linda Bosserman, and @drannekatz.bsky.social to do just that.
And thanks to @cancercaremascc.bsky.social for offering this!

Like I said, change is a good thing. Sad to leave Brown University Health but super excited to join such a venerable institution as @tuftsmedschool.bsky.social

Change is always a good thing. Well, maybe not always.
But when opportunities arise, they deserve to be explored.
Comfortable isn't synonymous with satisfied.

Sexual Health Course - MASCC/ISOO Annual Meeting 2025 Fundamentals of Sexual Health After Cancer: An Interactive Course Co-Chairs: Linda Bosserman and Anne Katz Additional Faculty: Don Dizon Duration: Wed Jun 25 – Thurs Jun 26Registration fee: $200 USDMa...

Come learn about cancer and its impact on sexuality. All are invited- you do not need to be an oncologist to discuss but all people with cancer deserve the chance to rediscover their sexual selves. Registration is OPEN for @cancercaremascc.bsky.social in #Seattle.

mascc.org/annualmeetin...

Fwiw. You don't need to be an MD to take this course or to help people with questions on their Sexual Health after cancer. You have to want to learn and willing to ask.